![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics of Dolutegravir After Switching to Abacavir/Dolutegravir/ Lamivudine From an Efavirenz-Based Regimen: A PK Sub-Study From STRIIVING
|
|
|
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; June 8-10, 2016; Washington, DC
Joss de Wet,1 Edwin DeJesus,2 Louis Sloan,3 Justin Koteff,4 Clare Brennan,4 Kimberly Adkison,4 Deanna Merrill,5 Brian Wynne,6 Mark Shaefer,4 Michael Aboud 7
1University of British Columbia, Vancouver, BC, Canada; 2Orlando Immunology Center, Orlando, FL, USA; 3North Texas Infectious Diseases Consultants, Dallas, TX, USA; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5ViiV Healthcare, Castle Rock, Colorado, USA; 6ViiV Healthcare, Collegeville, PA, USA; 7ViiV Healthcare, London, UK
![Clin1](../images/061516/061516-1/Clin1.gif)
![Clin2](../images/061516/061516-1/Clin2.gif)
![Clin3](../images/061516/061516-1/Clin3.gif)
ICAAC/2015: Switching to Abacavir/Dolutegravir/Lamivudine Fixed Dose Combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression - (09/21/15)
![Clin4](../images/061516/061516-1/Clin4.gif)
![Clin5](../images/061516/061516-1/Clin5.gif)
![Clin6](../images/061516/061516-1/Clin6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|